What is REGN's current stock price?

As of now, REGN is trading at $784.61, with a daily change of -0.34%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

REGN Stock Analysis & IQ Rating | Regeneron Pharmaceuticals

REGN

Regeneron Pharma

$784.61

-$2.71 | -0.34%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$800.99

MKT CAP

$79.75B

52W Low

$476.49

VOL

$869.55K

P/E Ratio

18.78

AVG VOL

$1.11M

RSI

79.45

TREND

Uptrend

REGN Stock IQ

Login to see Regeneron Pharma (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

REGN Target Price

Login to display

Strengths

REGN Rewards

Earnings are forecast to grow

REGN Rewards

Upgraded on attractively valued

REGN Rewards

Trading below its fair value

REGN Rewards

Outperform the market

Chart

$651.8 (+20.38%)

$567.22 (+38.33%)

$552.58 (+41.99%)

$773 (+1.50%)

1year

6month

3month

1month

REGN Risk Level

REGN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

REGN Analysts Opinion

REGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

REGN Analysts Opinion

REGN Analysts opinion is positive and also has improved from the past 3 months

REGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

88%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

75%

100%

81%

REGN Street Sentiment

REGN Street Sentiment is extremely bullish and have positive views on the near-term outlook

REGN Performance Sentiment

Sentiments overview associated with REGN events and the stock performance.

88%

5%

Positive

Negative

35 out of 40
events present

2 out of 40
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$755.90

Resistance
Price

$585.31

Current Price Range

$755.90

Show methods +

Linked to REGN

IQ

Close Price

Change

NVS

4.27

130.44

+0.15%

SNY

4.02

50.03

-0.50%

MRK

4.03

104.63

-0.97%

AZN

4.31

93.32

+0.09%

OPK

2.40

1.34

-0.74%

REGN Latest Analysis +

REGN Factor-Based Stock Analysis - Benjamin Graham. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Today

$784.61 | -0.34%

Potential

SNY & REGNs Dupixent Gets EU Nod for Chronic Spontaneous Urticaria. Sanofi/Regenerons Dupixent wins EU nod for chronic spontaneous urticaria marking its seventh approved indication across inflammatory diseases in the EU.

Tue Nov 25, 2025

$787.32 | +3.55%

Activity

Scotiabank Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation. Fintel reports that on November 24 2025 Scotiabank maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Sector Perform recommendation. Analyst Price Forecast Suggests 2.46% Upside

Tue Nov 25, 2025

$787.32 | +3.55%

Potential

Rating

Heres How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today. Regeneron Pharmaceuticals (NASDAQ:) has outperformed the market over the past 20 years by 14.96% on an annualized basis producing an average annual return of 23.64%. Currently Regeneron Pharmaceuticals has a market capitalization of $79.69 billion.

Mon Nov 24, 2025

$761.45 | +0.73%

Activity

HSBC Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Buy Recommendation. Fintel reports that on November 24 2025 HSBC initiated coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Buy recommendation. Analyst Price Forecast Suggests 2.46% Upside

Mon Nov 24, 2025

$761.45 | +0.73%

Rating

Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Mon Nov 24, 2025

$761.45 | +0.73%

Potential

REGN Crosses Above Average Analyst Target. In recent trading shares of Regeneron Pharmaceuticals Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $755.22 changing hands for $755.90/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react:

Mon Nov 24, 2025

$761.45 | +0.73%

Potential

Wells Fargo Maintains Regeneron Pharmaceuticals (REGN) Equal-Weight Recommendation. Fintel reports that on November 20 2025 Wells Fargo maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 5.07% Upside

Fri Nov 21, 2025

$755.90 | +2.56%

Potential

Rating

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss. On Wednesday the United States Food and Drug Administration (FDA) approved ) Eylea HD (aflibercept) Injection 8 mg for patients with following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing period.RVO is a blockage in one of the veins that drain blood from the retina causing blood and fluid to leak and potentially leading to vision loss.The FDA also app

Thu Nov 20, 2025

$737.00 | +5.23%

Activity

Potential

REGN Gets EC Nod for Libtayo Label Expansion FDA Clears Monthly Eylea HD. Regeneron gains EC approval to expand Libtayos use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.

Thu Nov 20, 2025

$737.00 | +5.23%

Activity

Potential

FAQ About REGN Stock Insights

What is REGN current stock price?

What are REGN stock strengths?

What is REGN Risk Level?

What is REGN market cap and volume?

What is REGN current Stock IQ?

Should I buy REGN stock right now?

Is REGN a Strong Buy right now?

What does a 'Strong Buy' rating mean for REGN?

What does a 'Strong Sell' rating mean for REGN?

What factors influence REGN's Stock IQ?

Explore our REGN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored REGN Stock Strategies
Effective Risk Management

FIND US ON

Receive our REGN Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

REGN

Regeneron Pharma

Current Price

$784.61

-$2.71 | -0.34%

52W High

$800.99

MKT CAP

$79.75B

52W Low

$476.49

VOL

$869.55K

P/E Ratio

18.78

AVG VOL

$1.11M

RSI

79.45

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

REGN Rewards

Earnings are forecast to grow

REGN Rewards

Upgraded on attractively valued

REGN Rewards

Trading below its fair value

REGN Rewards

Outperform the market

Linked to REGN

Symbol

IQ

Close

Change

NVS

4.27

130.44

+0.15%

SNY

4.02

50.03

-0.50%

MRK

4.03

104.63

-0.97%

AZN

4.31

93.32

+0.09%

OPK

2.40

1.34

-0.74%

REGN Stock IQ

Login to unlock Regeneron Pharma (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$651.8 (+20.38%)

$567.22 (+38.33%)

$552.58 (+41.99%)

$773 (+1.50%)

1year

6month

3month

1month

REGN Analysts Opinion

REGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

REGN Analysts Opinion

REGN Analysts opinion is positive and also has improved from the past 3 months

REGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

88%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

75%

100%

81%

REGN Street Sentiment

REGN Street Sentiment is extremely bullish and have positive views on the near-term outlook

REGN Risk Level

REGN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

REGN Performance Sentiment

Sentiments overview associated with REGN events and the stock performance.

88%

5%

Positive

Negative

35 out of 40
events present

2 out of 40
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$755.90

Resistance
Price

$585.31

Current Price Range

$755.90

Show methods +

REGN Latest Analysis

REGN Factor-Based Stock Analysis - Benjamin Graham. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Today

$784.61 | -0.34%

Potential

SNY & REGNs Dupixent Gets EU Nod for Chronic Spontaneous Urticaria. Sanofi/Regenerons Dupixent wins EU nod for chronic spontaneous urticaria marking its seventh approved indication across inflammatory diseases in the EU.

Tue Nov 25, 2025

$787.32 | +3.55%

Activity

Scotiabank Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation. Fintel reports that on November 24 2025 Scotiabank maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Sector Perform recommendation. Analyst Price Forecast Suggests 2.46% Upside

Tue Nov 25, 2025

$787.32 | +3.55%

Potential

Rating

Heres How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today. Regeneron Pharmaceuticals (NASDAQ:) has outperformed the market over the past 20 years by 14.96% on an annualized basis producing an average annual return of 23.64%. Currently Regeneron Pharmaceuticals has a market capitalization of $79.69 billion.

Mon Nov 24, 2025

$761.45 | +0.73%

Activity

HSBC Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Buy Recommendation. Fintel reports that on November 24 2025 HSBC initiated coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Buy recommendation. Analyst Price Forecast Suggests 2.46% Upside

Mon Nov 24, 2025

$761.45 | +0.73%

Rating

Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Mon Nov 24, 2025

$761.45 | +0.73%

Potential

REGN Crosses Above Average Analyst Target. In recent trading shares of Regeneron Pharmaceuticals Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $755.22 changing hands for $755.90/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react:

Mon Nov 24, 2025

$761.45 | +0.73%

Potential

Wells Fargo Maintains Regeneron Pharmaceuticals (REGN) Equal-Weight Recommendation. Fintel reports that on November 20 2025 Wells Fargo maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 5.07% Upside

Fri Nov 21, 2025

$755.90 | +2.56%

Potential

Rating

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss. On Wednesday the United States Food and Drug Administration (FDA) approved ) Eylea HD (aflibercept) Injection 8 mg for patients with following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly dosing period.RVO is a blockage in one of the veins that drain blood from the retina causing blood and fluid to leak and potentially leading to vision loss.The FDA also app

Thu Nov 20, 2025

$737.00 | +5.23%

Activity

Potential

REGN Gets EC Nod for Libtayo Label Expansion FDA Clears Monthly Eylea HD. Regeneron gains EC approval to expand Libtayos use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.

Thu Nov 20, 2025

$737.00 | +5.23%

Activity

Potential

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of REGN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our REGN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

REGN Stock trends

REGN Stock performance

REGN Stock analysis

REGN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing REGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing REGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

REGN Stock Analysis & IQ Rating | Regeneron Pharmaceuticals

REGN Stock IQ

REGN Target Price

REGN Risk Level

REGN Analysts Opinion

REGN Street Sentiment

REGN Performance Sentiment

Technical Price Levels

Explore our REGN Stock insights

Receive our REGN Daily Alerts

REGN Stock IQ

REGN Street Sentiment

REGN Risk Level

Technical Price Levels

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of REGN. We're here to help you make informed investment decisions today.

Receive our REGN Daily Alerts

REGN Runner Alarm